Table 1.

Summary of outcomes after partial gland ablation

Modality	Number of patients	Percentage of patients with clinically significant disease	Percentage of patients with negative follow-up biopsy	Failure-free survival (%)	Erectile function	Urinary function	Reference
Thermal
HIFU	625	84	75	88	15% new ED	83% pad-free at 3 y	Guillaumier et al, 2018
	164	80	N/A	96	18% new ED	0% new incontinence	Mistry et al, 2017
	149	89	N/A	83	14% new ED	0.6% new incontinence	Hanna et al, 2018
	111	32	93	89	22% new ED	3% new incontinence	Rischmann et al, 2017
Cryotherapy	301	62	N/A	95	No change	Improved flow rates	Bianco et al, 2018
	122	90	N/A	91	16% new ED	No change	Shah et al, 2019
	107	24	48	N/A	N/A	N/A	Barret et al, 2018
FLA	98	N/A	69	N/A	No change	No change	Feller et al, 2018
	25	56	84	N/A	No change	No change	Lepor et al, 2015
	18	N/A	28	66	No change	N/A	Elkhoury et al, 2018
RFA	21	N/A	76	N/A	No change	No change	Taneja et al, 2018
	20	N/A	80	90	No change	No change	Orczyk et al, 2018
Nonthermal
VTP	206	0	49	94	No change	No change	Azzouzi et al, 2015
	21	0	76	87	No change	No change	Taneja et al, 2018
Brachytherapy	354	17	N/A	N/A	N/A	N/A	King et al, 2018
IRE	25	28	72	8	No new ED	No change	Murray et al, 2016
	63	86	76	89	Mild decrease in scores (EPIC)	No change	van de Bos et al, 2018

ED, erectile dysfunction; EPIC, Expanded Prostate Cancer Index Composite; FLA, focal laser ablation; HIFU, high-intensity focused ultrasound; IRE, irreversible electroporation; N/A, not available; RFA, radiofrequency ablation; VTP, vascular-targeted photodynamic therapy.